Altachem Pharma Ltd. announces director slate

- Leading Canadian businessmen Don Rix and Rick Smith agree to stand for
election -

Trading Symbol: AAF:TSX Venture Exchange

EDMONTON, Aug. 10 /CNW/ - Altachem Pharma Ltd. ("Altachem" or "The
Company") today announces management's nominations for election to its Board
of Directors at its upcoming Annual and Special Shareholders' Meeting. In
addition to the current four board members, the slate includes Dr. Don Rix,
Chairman of MDS Metro Laboratory Services and Mr. Rick Smith, President & CEO
of Dow AgroSciences Canada.
"I'm delighted that we have been able to secure two such experienced and
high-calibre individuals as new Director-nominees" said Dr. David Cox,
President & CEO of Altachem. "The addition of Dr. Rix and Mr. Smith would
considerably strengthen our board and be another key step in the continued
rebuilding of our Company".
Dr. Rix is an active member of the biotechnology industry, having served
on the boards of many organizations, including various biotechnology and
technology companies. He recently received the Lifetime Leadership and
Achievement Award from the B.C. Biotechnology Alliance for his contributions
to the biotechnology sector. Dr. Rix is one of the owners and founders and
currently the Chairman of the Board of Directors of MDS Metro Laboratory
Services, the largest independent community medical laboratory in British
Columbia. He is also one of the owners and founders and currently Chairman of
Cantest Ltd. based in Vancouver, B.C. Dr. Rix currently serves on the B.C.
Innovation Council, B.C. Medical Services Foundation, and B.C. Children's
Hospital Foundation. He is also a board member of MDS Ventures Pacific Inc.,
Genyous Inc., Genome B.C. and B.C. Advantage Funds (VCC) Ltd. Dr. Rix received
a B.A. from the University of Western Ontario in 1953 and an MD in 1957. His
honors include a Fellowship in General Pathology (FRCP), College of General
Practice (Canada) honorary Life Membership, in 2001, an honorary Diploma of
Technology from the B.C. Institute of Technology in 1985, an honorary Doctor
of Technology from the B.C. Institute of Technology in 2003, the degree of
Doctor of Science, honoris causa from the University of Western Ontario in
1998, an honorary Doctor of Science from Simon Fraser University in 2004 and
the Order of B.C. in June, 2004.
Mr. Smith is the President and CEO of Dow AgroSciences Canada Inc., a
wholly owned subsidiary of The Dow Chemical Company. Mr. Smith has also held
senior management positions in the life sciences area, including human
pharmaceuticals, animal health and plant sciences with Eli Lilly and Company
and has been involved with several commercialization initiatives in plant
biotechnology. He is currently Chairman of the Board of SemBioSys Genetics
Inc. (TSX:SBS) and is an independent director of Commercial Solutions Inc.
(TSXV:CSA). Mr. Smith is also the founding chairman of BioProducts Canada Inc.
and is a director and Executive Committee member of each of: BIOTECanada,
BioAlberta, CropLife Canada and the Agricultural Warehousing Standards
Association. He attended the University of Waterloo where he received his
B.Sc. (Applied Chemistry) in 1971 and his M.Sc. (Biochemistry) in 1972.
The Company's Annual and Special Meeting will be held at 3:00 pm
(Edmonton time) on September 15, 2005 at the Greenwood Inn at 4485 Gateway
Blvd., Edmonton, Alberta. Information pertaining to the nomination of
Directors and other business matters will be mailed out in the coming weeks as
part of the materials for the meeting.

The complete list of Director nominations is as follows (alphabetical
order).

Dr. David Cox, President and CEO, Altachem Pharma Ltd.
Dr. Ragupathy ("Madi") Madiyalakan, President of BioStrat Inc.
Mr. Ian McConnan, Partner, Harris McConnan LLP
Dr. Selvaraj Naicker, Interim Chief Operating Officer, Altachem Pharma
 Ltd.
Dr. Don Rix, Chairman of MDS Metro Laboratory Services
Mr. Richard ("Rick") Smith, President and CEO, Dow AgroSciences Canada
 Inc.

About Altachem Pharma Ltd

The Corporation is a publicly traded (TSX Venture Exchange: AAF),   
Alberta-based pharmaceutical company committed to the development and
commercialization of new pharmaceutical products. It is developing a series of
products for the treatment of cancer and other proliferative diseases based on
its SonoLight and CDK platforms. It also has a profitable product in       
Accu-MAb(TM), a monoclonal-based diagnostic kit for whooping cough.

Except for historical information, this press release may contain   
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."

%SEDAR: 00008400E